Skip to main content

Table 4 Association of clinicopathological and treatment characteristics with time to tumor progression (univariate analysis)

From: Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Parameter

 

Patients (total)

Patients (progressed)

Time to progression (years)

p-value

TNM status at diagnosis

T0-T1

77

28

5.10

4.13- n.e.

0.1423

T2-T4

176

92

4.06

3.56-7.74

 

N0

74

37

4.11

3.30-6.05

0.2813

N1-N3

165

75

5.06

4.05-9.76

 

M0

171

79

5.06

4.05-9.70

0.2367

M1

64

31

4.39

3.51-6.58

Grading

G1-G2

132

63

4.13

3.55-6.05

0.3122

G3

118

55

5.06

4.04-9.53

Disease-free survival

0-5 years

203

91

5.12

4.11-8.72

0.2183

>5 years

56

32

3.46

3.00-4.44

Hormone receptor status

ER negative

109

48

5.96

4.04-9.53

0.1876

ER positive

148

73

4.13

3.55-6.05

 

PR negative

132

61

5.06

4.05-6.58

0.6547

PR positive

120

56

4.11

3.53-9.70

 

ER and PR negative

94

42

5.06

4.04-9.53

0.3789

ER or PR positive

157

75

4.18

3.56-6.58

Age at trastuzumab start

< 50 years

70

32

5.96

4.11-9.76

0.0744

≥50 years

198

94

4.20

3.56-6.05

ECOG status at trastuzumab start

0

115

54

4.61

3.91-9.76

0.0812

1-4

116

59

4.05

3.44-5.96

Site of recurrence at trastuzumab start

locoregional

    

0.1156

recurrent only

55

22

9.70

3.63-9.70

Bone metastases only

41

21

4.05

3.30-n.e.

Visceral metastases

139

69

4.39

3.55-6.58

Initial response to trastuzumab treatment

Complete remission

48

16

8.72

4.46-9.76

0.0571

Partial remission

80

46

4.03

3.50-4.41

Stable disease

82

37

4.66

3.56-n.e.

Interruption of trastuzumab treatment

no therapy interruption

251

109

5.13

4.11-9.53

0.0005

therapy interruption

14

14

3.51

2.36-4.44